Prothena Q3 net loss narrows 55% to $16.51 million
PRTA•Prothena’s third-quarter 2026 net loss narrowed 55% year over year to $16.51 million, while revenue fell 74% to $620,000. The company maintained full-year guidance for $18 million–$23 million in operating and investing cash use and approximately $259 million in year-end cash holdings.
1. Quarterly results
Prothena’s third-quarter 2026 net loss narrowed 55% year over year to $16.51 million, while revenue fell 74% to $620,000. Research and development expenses declined 71% to $8.43 million, attributed to lower clinical trial, personnel and consulting expenses.
2. Trial and cash outlook
Partner-led Phase 3 trials of prasinezumab for Parkinson’s disease and coramitug for ATTR-CM have primary completions expected in 2029. Prothena maintained full-year 2026 guidance for $18 million–$23 million in operating and investing cash use, with approximately $259 million in year-end cash holdings.
